| International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma S Kumar, B Paiva, KC Anderson, B Durie, O Landgren, P Moreau, ... The lancet oncology 17 (8), e328-e346, 2016 | 2889 | 2016 |
| The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms JD Khoury, E Solary, O Abla, Y Akkari, R Alaggio, JF Apperley, R Bejar, ... leukemia 36 (7), 1703-1719, 2022 | 2797 | 2022 |
| The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms R Alaggio, C Amador, I Anagnostopoulos, AD Attygalle, IBO Araujo, ... Leukemia 36 (7), 1720-1748, 2022 | 2549 | 2022 |
| Promiscuous mutations activate the noncanonical NF-κB pathway in multiple myeloma JJ Keats, R Fonseca, M Chesi, R Schop, A Baker, WJ Chng, S Van Wier, ... Cancer cell 12 (2), 131-144, 2007 | 1251 | 2007 |
| Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label … MA Dimopoulos, P Moreau, A Palumbo, D Joshua, L Pour, R Hájek, ... The Lancet Oncology 17 (1), 27-38, 2016 | 1056 | 2016 |
| Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group P Sonneveld, H Avet-Loiseau, S Lonial, S Usmani, D Siegel, ... Blood, The Journal of the American Society of Hematology 127 (24), 2955-2962, 2016 | 1022 | 2016 |
| Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study SK Kumar, JH Lee, JJ Lahuerta, G Morgan, PG Richardson, J Crowley, ... Leukemia 26 (1), 149-157, 2012 | 995 | 2012 |
| IMWG consensus on risk stratification in multiple myeloma WJ Chng, A Dispenzieri, CS Chim, R Fonseca, H Goldschmidt, ... Leukemia 28 (2), 269-277, 2014 | 738 | 2014 |
| A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer KP Ng, AM Hillmer, CTH Chuah, WC Juan, TK Ko, ASM Teo, ... Nature medicine 18 (4), 521-528, 2012 | 683 | 2012 |
| Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group M Cavo, E Terpos, C Nanni, P Moreau, S Lentzsch, S Zweegman, ... The lancet oncology 18 (4), e206-e217, 2017 | 533 | 2017 |
| P53 mutations in colorectal cancer-molecular pathogenesis and pharmacological reactivation XL Li, J Zhou, ZR Chen, WJ Chng World journal of gastroenterology: WJG 21 (1), 84, 2015 | 484 | 2015 |
| Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib G Mulligan, C Mitsiades, B Bryant, F Zhan, WJ Chng, S Roels, E Koenig, ... Blood 109 (8), 3177-3188, 2007 | 478 | 2007 |
| International Myeloma Working Group recommendations for the diagnosis and management of myeloma-related renal impairment MA Dimopoulos, P Sonneveld, N Leung, G Merlini, H Ludwig, E Kastritis, ... Journal of Clinical Oncology 34 (13), 1544-1557, 2016 | 476 | 2016 |
| Genetic aberrations and survival in plasma cell leukemia RE Tiedemann, N Gonzalez-Paz, RA Kyle, R Santana-Davila, ... Leukemia 22 (5), 1044-1052, 2008 | 471 | 2008 |
| AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies M Chesi, DF Robbiani, M Sebag, WJ Chng, M Affer, R Tiedemann, ... Cancer cell 13 (2), 167-180, 2008 | 465 | 2008 |
| Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial MA Dimopoulos, H Goldschmidt, R Niesvizky, D Joshua, WJ Chng, A Oriol, ... The lancet oncology 18 (10), 1327-1337, 2017 | 456 | 2017 |
| Telomerase directly regulates NF-κB-dependent transcription A Ghosh, G Saginc, SC Leow, E Khattar, EM Shin, TD Yan, M Wong, ... Nature cell biology 14 (12), 1270-1281, 2012 | 422 | 2012 |
| A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis SJ Kim, DH Yoon, A Jaccard, WJ Chng, ST Lim, H Hong, Y Park, ... The lancet oncology 17 (3), 389-400, 2016 | 385 | 2016 |
| Enabling technologies for personalized and precision medicine D Ho, SR Quake, ERB McCabe, WJ Chng, EK Chow, X Ding, BD Gelb, ... Trends in biotechnology 38 (5), 497-518, 2020 | 364 | 2020 |
| Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study SK Kumar, MA Dimopoulos, E Kastritis, E Terpos, H Nahi, H Goldschmidt, ... Leukemia 31 (11), 2443-2448, 2017 | 353 | 2017 |
